184 related articles for article (PubMed ID: 30596759)
1. A genetically engineered microRNA-34a prodrug demonstrates anti-tumor activity in a canine model of osteosarcoma.
Alegre F; Ormonde AR; Snider KM; Woolard K; Yu AM; Wittenburg LA
PLoS One; 2018; 13(12):e0209941. PubMed ID: 30596759
[TBL] [Abstract][Full Text] [Related]
2. Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest.
Zhao Y; Tu MJ; Wang WP; Qiu JX; Yu AX; Yu AM
Sci Rep; 2016 May; 6():26611. PubMed ID: 27216562
[TBL] [Abstract][Full Text] [Related]
3. MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines.
Lopez CM; Yu PY; Zhang X; Yilmaz AS; London CA; Fenger JM
PLoS One; 2018; 13(1):e0190086. PubMed ID: 29293555
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth.
Zhao Y; Tu MJ; Yu YF; Wang WP; Chen QX; Qiu JX; Yu AX; Yu AM
Biochem Pharmacol; 2015 Dec; 98(4):602-13. PubMed ID: 26518752
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-34a inhibits tumor invasion and metastasis in osteosarcoma partly by effecting C-IAP2 and Bcl-2.
Wen J; Zhao YK; Liu Y; Zhao JF
Tumour Biol; 2017 Jun; 39(6):1010428317705761. PubMed ID: 28635396
[TBL] [Abstract][Full Text] [Related]
6. MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines.
Fenger JM; Roberts RD; Iwenofu OH; Bear MD; Zhang X; Couto JI; Modiano JF; Kisseberth WC; London CA
BMC Cancer; 2016 Oct; 16(1):784. PubMed ID: 27724924
[TBL] [Abstract][Full Text] [Related]
7. A novel small-molecule antagonist enhances the sensitivity of osteosarcoma to cabozantinib in vitro and in vivo by targeting DNMT-1 correlated with disease severity in human patients.
Wang JH; Zeng Z; Sun J; Chen Y; Gao X
Pharmacol Res; 2021 Nov; 173():105869. PubMed ID: 34481973
[TBL] [Abstract][Full Text] [Related]
8. Long Noncoding RNA SNHG7 Promotes the Tumor Growth and Epithelial-to-Mesenchymal Transition via Regulation of miR-34a Signals in Osteosarcoma.
Deng Y; Zhao F; Zhang Z; Sun F; Wang M
Cancer Biother Radiopharm; 2018 Nov; 33(9):365-372. PubMed ID: 29989838
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis.
Liu X; Luo X; Wu Y; Xia D; Chen W; Fang Z; Deng J; Hao Y; Yang X; Zhang T; Zhou L; Wu Y; Wang Q; Xu J; Hu X; Li L
Cell Physiol Biochem; 2018; 50(1):261-276. PubMed ID: 30282072
[TBL] [Abstract][Full Text] [Related]
10. Bioengineering Novel Chimeric microRNA-34a for Prodrug Cancer Therapy: High-Yield Expression and Purification, and Structural and Functional Characterization.
Wang WP; Ho PY; Chen QX; Addepalli B; Limbach PA; Li MM; Wu WJ; Jilek JL; Qiu JX; Zhang HJ; Li T; Wun T; White RD; Lam KS; Yu AM
J Pharmacol Exp Ther; 2015 Aug; 354(2):131-41. PubMed ID: 26022002
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-34a attenuates VEGF-mediated retinal angiogenesis via targeting Notch1.
Shi S; Jin Y; Song H; Chen X
Biochem Cell Biol; 2019 Aug; 97(4):423-430. PubMed ID: 30571142
[TBL] [Abstract][Full Text] [Related]
12. The Microtubule Network and Cell Death Are Regulated by an miR-34a/Stathmin 1/βIII-Tubulin Axis.
Vetter NS; Kolb EA; Mills CC; Sampson VB
Mol Cancer Res; 2017 Jul; 15(7):953-964. PubMed ID: 28275089
[TBL] [Abstract][Full Text] [Related]
13. p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expression.
Novello C; Pazzaglia L; Conti A; Quattrini I; Pollino S; Perego P; Picci P; Benassi MS
PLoS One; 2014; 9(12):e114757. PubMed ID: 25490093
[TBL] [Abstract][Full Text] [Related]
14. miR-34a increases cisplatin sensitivity of osteosarcoma cells in vitro through up-regulation of c-Myc and Bim signal.
Li QC; Xu H; Wang X; Wang T; Wu J
Cancer Biomark; 2017 Dec; 21(1):135-144. PubMed ID: 29060932
[TBL] [Abstract][Full Text] [Related]
15. The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene.
Pu Y; Zhao F; Li Y; Cui M; Wang H; Meng X; Cai S
BMC Cancer; 2017 Jan; 17(1):45. PubMed ID: 28073349
[TBL] [Abstract][Full Text] [Related]
16. Diallyl trisulfide inhibits proliferation, invasion and angiogenesis of osteosarcoma cells by switching on suppressor microRNAs and inactivating of Notch-1 signaling.
Li Y; Zhang J; Zhang L; Si M; Yin H; Li J
Carcinogenesis; 2013 Jul; 34(7):1601-10. PubMed ID: 23430952
[TBL] [Abstract][Full Text] [Related]
17. The Optimal Outcome of Suppressing Ewing Sarcoma Growth
Li DF; Yuan Y; Tu MJ; Hu X; Li YZ; Yi WR; Li PC; Zhao Y; Cheng Z; Yu AM; Jian C; Yu AX
Front Oncol; 2020; 10():222. PubMed ID: 32161722
[TBL] [Abstract][Full Text] [Related]
18. The potential combinational effect of miR-34a with celecoxib in osteosarcoma.
Chen X; Peng D; Shen Y; Liu B; Zhou H; Tao H; Huang J
Anticancer Drugs; 2017 Sep; 28(8):888-897. PubMed ID: 28650862
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-661 Enhances TRAIL or STS Induced Osteosarcoma Cell Apoptosis by Modulating the Expression of Cytochrome c1.
Fan L; Zhu C; Qiu R; Zan P; Zheng Z; Xu T; Li G
Cell Physiol Biochem; 2017; 41(5):1935-1946. PubMed ID: 28391262
[TBL] [Abstract][Full Text] [Related]
20. MiR-34a-5p promotes multi-chemoresistance of osteosarcoma through down-regulation of the DLL1 gene.
Pu Y; Zhao F; Wang H; Cai S
Sci Rep; 2017 Mar; 7():44218. PubMed ID: 28281638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
